Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$181.4 million.

  • ImmunityBio's Cash from Investing Activities fell 37887.96% to -$181.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$183.5 million, marking a year-over-year decrease of 82552.06%. This contributed to the annual value of -$12.2 million for FY2024, which is 5980.96% up from last year.
  • As of Q3 2025, ImmunityBio's Cash from Investing Activities stood at -$181.4 million, which was down 37887.96% from -$16.1 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Cash from Investing Activities ranged from a high of $116.7 million in Q2 2022 and a low of -$181.4 million during Q3 2025
  • Over the past 5 years, ImmunityBio's median Cash from Investing Activities value was -$8.5 million (recorded in 2023), while the average stood at -$15.5 million.
  • In the last 5 years, ImmunityBio's Cash from Investing Activities plummeted by 192640.16% in 2021 and then soared by 101232.72% in 2022.
  • Over the past 5 years, ImmunityBio's Cash from Investing Activities (Quarter) stood at -$137.8 million in 2021, then surged by 86.29% to -$18.9 million in 2022, then surged by 111.9% to $2.2 million in 2023, then surged by 337.26% to $9.8 million in 2024, then crashed by 1944.22% to -$181.4 million in 2025.
  • Its Cash from Investing Activities stands at -$181.4 million for Q3 2025, versus -$16.1 million for Q2 2025 and $4.1 million for Q1 2025.